OptimizeRx Corporation

NASDAQ:OPRX

Medical - Healthcare Information Services

Healthcare
$7.31 -0.98%

-$0.05 today

Market cap
$138.21M
Beta
1.10
P/E (TTM)
13.8
EPS (TTM)
$0.36
52W Low $4.57High $22.25

Volume 0.18M

Average 0.47M

OPRX EBITDA Margin

EBITDA as a percentage of revenue.

OptimizeRx CorporationNASDAQ: OPRX

EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026

EBITDA Margin widens to 7.9%

EBITDA Margin was 7.9% in Q1 FY2026, up 12.0 pp from a year earlier. On a trailing-twelve-month basis it was 17.6%, up 23.8 pp year over year. Over 3 fiscal years it widened by 30.2 pp.

Context

  • EBITDA Margin widened in 2 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 5 analysts of 29.5% for the fiscal year ending Dec 2026, up from 15.1% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
7.9%-22.4 pp QoQ
Last fiscal yearDec 2025
15.1%+24.8 pp YoY
LTMMar 2026
17.6%+23.8 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+12.0 pp+7.7 pp-4.3 pp
1 year+24.8 pp+14.4 pp-10.4 pp
3 years+30.2 pp+14.0 pp-16.2 pp
5 years——
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
15.1%
Year-over-year change
+24.8pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How OPRX compares with its peers on the latest reported figures

  • OPRX's LTM Mar 2026 EBITDA Margin of 17.6% is the 3rd highest of the 9 companies compared; the peer median is 7.1%.
  • Its year-over-year change of +23.8 pp is the 2nd highest of 9, against a peer median of -4.8 pp.
  • Over three fiscal years its change of +30.2 pp compares with a peer median of -6.4 pp.
OPRX Competitors Peer median
EBITDA Margin for OPRX and competitors
Company Period LTM level YoY 3-year change
SLPSimulations Plus, Inc.LTM Feb 202621.5% +0.4 pp-16.1 pp
NRCNational Research CorporationLTM Mar 202620.1% -9.1 pp-10.5 pp
OPRXOptimizeRx CorporationLTM Mar 202617.6% +23.8 pp+30.2 pp
SPOKSpok Holdings, Inc.LTM Mar 202616.3% -1.8 pp+14.4 pp
TBRGTruBridge, Inc.LTM Mar 20269.4% -3.3 pp-2.4 pp
DHDefinitive Healthcare Corp.LTM Mar 20264.9% +295.3 pp-78.9 pp
RXSTRxSight, Inc.LTM Mar 2026-33.9% -19.3 pp+89.0 pp
SOPHSOPHiA GENETICS S.A.LTM Mar 2026-81.4% -6.3 pp+87.8 pp
NAKANakamoto Inc.LTM Mar 2026-7060.9% -6900.9 pp-2402.8 pp
DRUGBright Minds Biosciences Inc.FY2025— ——
Peer median (excluding OPRX) 7.1%-4.8 pp-6.4 pp

Competitors are the stored peer set for OPRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue61.29M62.45M71.52M92.13M109.43M
Cost of Revenue25.65M23.48M28.62M32.75M40.16M
Gross Profit35.64M38.97M42.9M59.38M69.27M
Gross Margin58.1%62.4%60.0%64.5%63.3%
Research & Development00000
Selling, General & Admin33.19M49.24M58.02M61.27M50.25M
Operating Expenses35.28M51.26M69.3M73.08M57.21M
Depreciation & Amortization1.97M2.02M2.4M4.33M4.33M
EBITDA2.34M(9.42M)(21.31M)(8.9M)16.57M
EBITDA Margin3.8%-15.1%-29.8%-9.7%15.1%
Operating Income361.1K(12.29M)(26.4M)(13.71M)12.06M
Operating Margin0.6%-19.7%-36.9%-14.9%11.0%
Interest Income16.98K852.3K2.19M329K353K
Interest Expense001.45M6.16M5.29M
Other Income / Expenses16.98K852.3K1.24M(5.68M)(5.11M)
Income Before Tax378.08K(11.44M)(25.16M)(19.39M)6.95M
Pre-Tax Margin0.6%-18.3%-35.2%-21.0%6.4%
Income Tax Expense00(7.6M)725K1.82M
Net Income378.08K(11.44M)(17.57M)(20.11M)5.13M
Net Margin0.6%-18.3%-24.6%-21.8%4.7%
EPS (Basic)0.02(0.64)(1.03)(1.10)0.28
EPS (Diluted)0.02(0.64)(1.03)(1.10)0.27
Weighted Avg Shares17.23M17.78M17.12M18.29M18.56M
Weighted Avg Shares (Diluted)17.69M17.78M17.12M18.29M19M

OptimizeRx Corporation

NASDAQ:OPRX

Intrinsic Alpha fair value

Locked

Current Price

$7.31

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.